“Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
SUMMARY Glucose and fructose are closely related simple sugars, but fructose has been associated more closely with metabolic disease. Until the 1960s, the major dietary source of fructose was fruit, but subsequently, high-fructose corn syrup (HFCS) became a dominant component of the Western diet. The exponential increase in HFCS consumption correlates with the increased incidence of obesity and type 2 diabetes mellitus, but the mechanistic link between these metabolic diseases and fructose remains tenuous. Although dietary fructose was thought to be metabolized exclusively in the liver, evidence has emerged that it is also metabolized in the small intestine and leads to intestinal epithelial barrier deterioration. Along with the clinical manifestations of hereditary fructose intolerance, these findings suggest that, along with the direct effect of fructose on liver metabolism, the gut-liver axis plays a key role in fructose metabolism and pathology. Here, we summarize recent studies on fructose biology and pathology and discuss new opportunities for prevention and treatment of diseases associated with high-fructose consumption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Self-citationGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Self-citationStanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 11×
“Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.”
BackgroundInfluentialSelf-citationMetabolic Effects of Fructose and the Worldwide Increase in Obesity
Tappy, L., & Lê, K.-A. (2010) · Physiological Reviews · doi:10.1152/physrev.00019.2009 · Cited by 1,256
Dhingra, R., Sullivan, L., Jacques, P. F., Wang, T. J., Fox, C. S., Meigs, J. B., D’Agostino, R. B., Gaziano, J. M., & Vasan, R. S. (2007) · Circulation · doi:10.1161/circulationaha.107.689935 · Cited by 918
Carey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898
Self-citationKammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732 · cited 2×
“, 2020) and others (Kammoun et al., 2009; Lee et al., 2008) has demonstrated that fructose can induce endoplasmic reticulum (ER) stress, which, in turn, can drive hepatosteatosis (Nakagawa et al.”
BackgroundThe Small Intestine Converts Dietary Fructose into Glucose and Organic Acids
Jang, C., Hui, S., Lu, W., Cowan, A. J., Morscher, R. J., Lee, G., Liu, W., Tesz, G. J., Birnbaum, M. J., & Rabinowitz, J. D. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.12.016 · Cited by 639 · cited 2×
“The same authors previously observed that fructose is converted to acetate by the microbiota (Jang et al., 2018) and that acetate can generate acetyl-CoA independent of ACLY (Zhao et al.”
BackgroundA gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
Self-citationSweetened beverage consumption and risk of coronary heart disease in women
Fung, T. T., Malik, V., Rexrode, K. M., Manson, J. E., Willett, W. C., & Hu, F. B. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27140 · Cited by 601 · cited 1×
“Although females were somewhat protected compared with men, the Nurse Health study of over 88,000 women also demonstrated that regular consumption of fructose in the form of soft drinks is associated with a higher CVD risk, even after other unhealthful lifestyle or dietary factors were accounted for (Fung et al., 2009…”
ResultFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561 · cited 13×
“Regulation of the fructose transporter GLUT5 in health and disease.”
BackgroundInfluentialDietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553 · cited 7×
“, 2020), using comparatively low amounts of fructose, found that enterocyte-specific KHK-C deficiency was not protective, but hepatic steatosis was quite low in these experiments, as also observed previously (Zhao et al., 2020).”
BackgroundResultInfluentialTrial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M. A., Seki, E., Hidalgo, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.001 · Cited by 525
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498 · cited 1×
“, 2017), whereas bempedoic acid (Nexletol), an ACLY inhibitor, is a clinically approved drug to treat hypercholesterolemia, as it lowers LDL cholesterol and attenuates atherosclerosis (Pinkosky et al., 2016).”
BackgroundKim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419
ATP-citrate lyase controls a glucose-to-acetate metabolic switch
Zhao, S., Torres, A., Henry, R. A., Trefely, S., Wallace, M., Lee, J. V., Carrer, A., Sengupta, A., Campbell, S. L., Kuo, Y.-M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.069 · Cited by 394
High-fructose corn syrup enhances intestinal tumor growth in mice
Goncalves, M. D., Lu, C., Tutnauer, J., Hartman, T. E., Hwang, S.-K., Murphy, C. J., Pauli, C., Morris, R., Taylor, S., Bosch, K., et al. (2019) · Science · doi:10.1126/science.aat8515 · Cited by 374 · cited 2×
“, 2020) and others (Goncalves et al., 2019) demonstrated that high fructose consumption can promote liver and colorectal tumorigenesis.”
BackgroundBruce, C. R., Hoy, A. J., Turner, N., Watt, M. J., Allen, T. L., Carpenter, K., Cooney, G. J., Febbraio, M. A., & Kraegen, E. W. (2009) · Diabetes · doi:10.2337/db08-1078 · Cited by 363
Self-citationInterleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334 · cited 1×
“, 2006), further reducing hepatic steatosis (Matthews et al., 2010).”
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333 · cited 3×
“ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P.”
BackgroundSelf-citationFructose stimulated de novo lipogenesis is promoted by inflammation
Todoric, J., Di Caro, G., Reibe, S., Henstridge, D. C., Green, C. R., Vrbanac, A., Ceteci, F., Conche, C., McNulty, R., Shalapour, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0261-2 · Cited by 328
Self-citationLoomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology · doi:10.1002/hep.31622 · Cited by 296 · cited 1×
“In patients with bridging fibrosis and cirrhosis, 48 weeks of Cilofexor/Firsocostat was well tolerated and led to improvements in NASH activity but did not meet the antifibrotic target to conclude that the trial was successful (Loomba et al., 2021).”
BackgroundHarrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280 · cited 1×
“, 2014), reduced liver fat with a mild improvement in fibrosis (Harrison et al., 2021).”
BackgroundKraakman, M. J., Kammoun, H. L., Allen, T. L., Deswaerte, V., Henstridge, D. C., Estevez, E., Matthews, V. B., Neill, B., White, D. A., Murphy, A. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.006 · Cited by 257
Self-citationGeidl-Flueck, B., Hochuli, M., Németh, Á., Eberl, A., Derron, N., Köfeler, H. C., Tappy, L., Berneis, K., Spinas, G. A., & Gerber, P. A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.027 · Cited by 238 · cited 1×
“These pre-clinical studies have recently been verified in a randomized-controlled study in humans (Geidl-Flueck et al., 2021).”
BackgroundHepatic expression and cellular distribution of the glucose transporter family
Karim, S. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i46.6771 · Cited by 190 · cited 1×
“, 2012) because GLUT5 is not well expressed in this tissue (Karim et al., 2012).”
BackgroundIncomplete absorption of pure fructose in healthy subjects and the facilitating effect of glucose.
Truswell, A., Seach, J., & Thorburn, A. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.6.1424 · Cited by 189 · cited 1×
“, 1983), particularly if the fructose is free and not ingested as sucrose (Truswell et al., 1988).”
BackgroundSeparating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183
Intestinal Absorption of Fructose
Ferraris, R. P., Choe, J.-Y., & Patel, C. R. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051707 · Cited by 180
Spruss, A., Kanuri, G., Stahl, C., Bischoff, S. C., & Bergheim, I. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.75 · Cited by 168
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.06.001 · Cited by 94 · cited 1×
“Recently, it was found to improve multiple NASH markers, including steatosis, inflammation, and fibrosis in both human primary hepatocytes and rats in vivo (Ross et al., 2020).”
BackgroundTreatment of type 2 diabetes with the designer cytokine IC7Fc
Findeisen, M., Allen, T. L., Henstridge, D. C., Kammoun, H., Brandon, A. E., Baggio, L. L., Watt, K. I., Pal, M., Cron, L., Estevez, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1601-9 · Cited by 86 · cited 3×
“IC7Fc prevented high-fat-diet-induced insulin resistance and NAFLD, while preserving muscle mass through YAP activation (Findeisen et al., 2019).”
BackgroundMethodInfluentialInsights into the Hexose Liver Metabolism—Glucose versus Fructose
Geidl-Flueck, B., & Gerber, P. (2017) · Nutrients · doi:10.3390/nu9091026 · Cited by 85 · cited 1×
“Unlike glucose, which is mobilized by phosphofructokinase and glucokinase, the latter being an enzyme whose activity is subject to feedback inhibition and regulation by insulin, fructose is mobilized by the faster and constitutively active enzyme fructokinase (also known as ketohexokinase or KHK) (Geidl-Flueck and Ger…”
BackgroundAyoub-Charette, S., Liu, Q., Khan, T. A., Au-Yeung, F., Blanco Mejia, S., de Souza, R. J., Wolever, T. M., Leiter, L. A., Kendall, C., & Sievenpiper, J. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024171 · Cited by 67 · cited 1×
“It was also proposed that fructose induces hyperuricemia and that this may not only result in hypertension but can also increase gout prevalence (Ayoub-Charette et al., 2019; Johnson et al., 2003).”
BackgroundIncreased visceral adipocyte lipolysis--a pathogenic role in nonalcoholic fatty liver disease?
Thörne, A., Löfgren, P., & Hoffstedt, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0520 · Cited by 25
Cited by
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Obesity-induced inflammation: connecting the periphery to the brain
Le Thuc, O., & García-Cáceres, C. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01079-8 · Cited by 125
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
“These are then synthesized into triacylglyceride (TAG) via conjugation with glycerol-3 phosphate (G3P), leading to the formation of lipid droplets in the liver.(2)”
BackgroundMethodInfluentialSelf-citationTherapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Boslem, E., Reibe, S., Carlessi, R., Smeuninx, B., Tegegne, S., Egan, C. L., McLennan, E., Terry, L. V., Nobis, M., Mu, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0831 · Cited by 39
“As we have recently discussed ( 11 ), these strategies have led to some promising drug candidates, but many have failed in late phase clinical trials due to adverse side effects such as hyperlipidemia and/or hypercholesterolemia.”
Self-citation
Metadata
- Authors
- Febbraio, M. A., & Karin, M.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 33
- Issue
- 12
- Pages
- 2316-2328
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W3202816718
- Cited by
- 173
- References
- 39
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.